$1.91 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter

Wall Street brokerages expect Celldex Therapeutics, Inc. (NASDAQ:CLDX) to announce $1.91 million in sales for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Celldex Therapeutics’ earnings, with the highest sales estimate coming in at $2.11 million and the lowest estimate coming in at $1.70 million. Celldex Therapeutics reported sales of $1.87 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.1%. The firm is scheduled to issue its next earnings report on Tuesday, March 13th.

On average, analysts expect that Celldex Therapeutics will report full year sales of $1.91 million for the current financial year, with estimates ranging from $9.30 million to $11.40 million. For the next year, analysts anticipate that the company will post sales of $13.57 million per share, with estimates ranging from $100,000.00 to $34.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that cover Celldex Therapeutics.

CLDX has been the subject of several analyst reports. BidaskClub lowered Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Thursday, January 11th. WBB Securities reiterated a “buy” rating and set a $10.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, December 6th. Finally, HC Wainwright set a $10.00 price objective on Celldex Therapeutics and gave the company a “buy” rating in a report on Friday, February 9th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $7.05.

Shares of Celldex Therapeutics (NASDAQ CLDX) opened at $2.29 on Thursday. Celldex Therapeutics has a twelve month low of $2.20 and a twelve month high of $3.94. The company has a market capitalization of $311.41, a price-to-earnings ratio of -2.27 and a beta of 2.57.

Hedge funds have recently modified their holdings of the stock. Northern Trust Corp raised its stake in Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after acquiring an additional 219,661 shares during the last quarter. Virtu KCG Holdings LLC raised its stake in Celldex Therapeutics by 458.6% in the 2nd quarter. Virtu KCG Holdings LLC now owns 117,770 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 96,687 shares during the last quarter. Vanguard Group Inc. raised its stake in Celldex Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after acquiring an additional 708,095 shares during the last quarter. Meditor Group Ltd raised its stake in Celldex Therapeutics by 8.8% in the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after acquiring an additional 512,700 shares during the last quarter. Finally, Swiss National Bank raised its stake in Celldex Therapeutics by 27.4% in the 2nd quarter. Swiss National Bank now owns 203,700 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 43,800 shares during the last quarter. Institutional investors own 52.14% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/15/1-91-million-in-sales-expected-for-celldex-therapeutics-inc-cldx-this-quarter.html.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Get a free copy of the Zacks research report on Celldex Therapeutics (CLDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply